TY - JOUR
TI - Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
AU - Hatzakis, A.
AU - Karabinis, A.
AU - Roussos, S.
AU - Pantazis, N.
AU - Degiannis, D.
AU - Chaidaroglou, A.
AU - Petsios, K.
AU - Pavlopoulou, I.
AU - Tsiodras, S.
AU - Paraskevis, D.
AU - Sypsa, V.
AU - Psichogiou, M.
JO - Vaccine
PY - 2022
VL - 10
TODO - 2
SP - null
PB - MDPI
SN - 0264-410X
TODO - 10.3390/vaccines10020285
TODO - C reactive protein;  diltiazem;  immunoglobulin G;  tozinameran, adult;  antigen binding;  Article;  blood sampling;  chemiluminescence immunoassay;  controlled study;  exponential model;  female;  health care personnel;  human;  immune response;  immunogenicity;  immunoglobulin blood level;  immunosuppressive treatment;  kinetics;  male;  model selection;  nonhuman;  power law model;  questionnaire;  restricted cubic splines model;  Severe acute respiratory syndrome coronavirus 2;  statistical analysis;  vaccination
TODO - Several lines of evidence suggest that binding SARS-CoV-2 antibodies such as anti-SARSCoV-2 RBD IgG (anti-RBD) and neutralising antibodies (NA) are correlates of protection against SARS-CoV-2, and the correlation of anti-RBD and NA is very high. The effectiveness (VE) of BNT162b2 in preventing SARS-CoV-2 infection wanes over time, and this reduction is mainly associated with waning immunity, suggesting that the kinetics of antibodies reduction might be of interest to predict VE. In a study of 97 health care workers (HCWs) vaccinated with the BNT162b2 vaccine, we assessed the kinetics of anti-RBD 30–250 days after vaccination using 388 individually matched plasma samples. Anti-RBD levels declined by 85%, 92%, and 95% at the 4th, 6th, and 8th month from the peak, respectively. The kinetics were estimated using the trajectories of anti-RBD by various models. The restricted cubic splines model had a better fit to the observed data. The trajectories of anti-RBD declines were statistically significantly lower for risk factors of severe COVID-19 and the absence of vaccination side effects. Moreover, previous SARS-CoV-2 infection was associated with divergent trajectories consistent with a slower anti-RBD decline over time. These results suggest that anti-RBD may serve as a harbinger for vaccine effectiveness (VE), and it should be explored as a predictor of breakthrough infections and VE. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
ER -